News New cystic fibrosis triple from Vertex backed for NHS use Vertex has won NICE's backing for a new cystic fibrosis therapy, Alyftrek, that could be an option for 89% of NHS patients with the genetic disorder.
News NICE backs new drugs for Crohn's disease, lymphoma Eli Lilly's Omvoh has been recommended for use in Crohn's disease by NICE, while BeOne's Brukinsa gets the go-ahead for mantle cell lymphoma.
News NICE relents on Takeda colorectal cancer drug Fruzaqla Colorectal cancer patients could soon have access via the NHS to a targeted oral drug that can give them more precious time with their loved ones.
News New passport 'will speed medtech rollout in NHS' The UK has revealed a new 'innovator passport' designed to accelerate the rollout of proven medtech in the NHS.
News Dismay but little surprise as NICE rejects Alzheimer's drugs Eli Lilly and Eisai's hopes of making their Alzheimer's disease therapies available to NHS patients in England have been knocked back once again.
News Guidance creates access gap in UK for GPP drug Spevigo People in England and Wales with severe skin disease GPP will soon be able to access a new therapy currently denied to patients in Scotland.
R&D Ben Sidders on integrating causality in AI for R&D success Ben Sidders, chief scientific officer at Biorelate, discusses leveraging advanced data science methods to transform the focus and impact of R&D.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face